EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A modified BPaL regimen for tuberculosis treatment replaces linezolid with inhaled spectinamides

Malik Zohaib Ali iD, Taru S Dutt, Amy MacNeill, Amanda Walz, Camron Pearce, Ha Lam, Jamie S Philp, Johnathan Patterson, Marcela Henao-Tamayo, Richard Lee, Jiuyu Liu, Gregory T Robertson und 3 weitere

eLife · 2024

DOI: 10.7554/elife.96190 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, 2024. Verfasst von Malik Zohaib Ali und 14 weiteren Autor:innen. Beteiligte Einrichtung: Mycobacteria Research Laboratories, Colorado State University, Fort Collins, United States. Hauptthemen laut MEDLINE: Antitubercular Agents, Linezolid, Mice, Inbred BALB C, Disease Models, Animal. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ORIP NIH HHS, NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Nix-TB clinical trial evaluated a new 6 month regimen containing three oral drugs; bedaquiline (B), pretomanid (Pa), and linezolid (L) (BPaL regimen) for the treatment of tuberculosis (TB). This regimen achieved remarkable results as almost 90% of the multidrug-resistant or extensively drug-resistant TB participants were cured but many patients also developed severe adverse events (AEs). The AEs were associated with the long-term administration of the protein synthesis inhibitor linezolid. Spectinamide 1599 is also a protein synthesis inhibitor of Mycobacterium tuberculosis with an excellent safety profile, but it lacks oral bioavailability. Here, we propose to replace L in the BPaL regimen with spectinamide (S) administered via inhalation and we demonstrate that inhaled spectinamide 1599, combined with BPa ––BPaS regimen––has similar efficacy to that of the BPaL regimen while simultaneously avoiding the L-associated AEs. The BPaL and BPaS regimens were compared in the BALB/c and C3HeB/FeJ murine chronic TB efficacy models. After 4-weeks of treatment, both regimens promoted equivalent bactericidal effects in both TB murine models. However, treatment with BPaL resulted in significant weight loss and the complete blood count suggested the development of anemia. These effects were not similarly observed in mice treated with BPaS. BPaL and BPa, but not the BPaS treatment, also decreased myeloid to erythroid ratio suggesting the S in the BPaS regimen was able to recover this effect. Moreover, the BPaL also increased concentration of proinflammatory cytokines in bone marrow compared to mice receiving BPaS regimen. These combined data suggest that inhaled spectinamide 1599 combined with BPa is an effective TB regimen without L-associated AEs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antitubercular AgentsLinezolidMice, Inbred BALB CDisease Models, AnimalAnimalsAdministration, InhalationMiceMycobacterium tuberculosisSpectinomycinTuberculosisDiarylquinolinesFemaleTreatment OutcomeMice, Inbred C3HDrug Therapy, CombinationNitroimidazoles

Stichwörter der Autor:innen

Mycobacteriumbedaquiline/pretomanidinfectious diseaseinhalationlinezolidmicrobiologyspectinmaidestuberculosis

Substanzen

Antitubercular AgentsLinezolidbedaquilineSpectinomycinDiarylquinolinespretomanidNitroimidazoles

Autor:innen und Institutionen

  • Mycobacteria Research Laboratories, Colorado State University, Fort Collins, United States.
  • Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, United States.
  • Program in Cell & Molecular Biology, Colorado State University, Fort Collins, United States.
  • Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, United States.
  • Technology Advancement and Commercialization, RTI International, Research Triangle Park, United States.
  • Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, United States.

ORCID-Profile: Malik Zohaib Ali, Mercedes Gonzalez Juarrero

Förderung

  • ORIP NIH HHS
  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • Fulbright U.S. Student Program
  • NIH HHS
  • Office of Research Infrastructure Programs

Zitieren

APA

Zohaib Ali, M., Dutt, T. S., MacNeill, A., Walz, A., Pearce, C., Lam, H., Philp, J. S., Patterson, J., Henao-Tamayo, M., Lee, R., Liu, J., Robertson, G. T., Hickey, A. J., Meibohm, B., & Gonzalez Juarrero, M. (2024). A modified BPaL regimen for tuberculosis treatment replaces linezolid with inhaled spectinamides. eLife. https://doi.org/10.7554/elife.96190

Vancouver

Zohaib Ali M, Dutt TS, MacNeill A, Walz A, Pearce C, Lam H, et al. A modified BPaL regimen for tuberculosis treatment replaces linezolid with inhaled spectinamides. eLife. 2024. doi:10.7554/elife.96190

BibTeX
@article{ZohaibAli2024,
  author = {Zohaib Ali, Malik and Dutt, Taru S and MacNeill, Amy and Walz, Amanda and Pearce, Camron and Lam, Ha and Philp, Jamie S and Patterson, Johnathan and Henao-Tamayo, Marcela and Lee, Richard and Liu, Jiuyu and Robertson, Gregory T and Hickey, Anthony J and Meibohm, Bernd and Gonzalez Juarrero, Mercedes},
  title = {A modified BPaL regimen for tuberculosis treatment replaces linezolid with inhaled spectinamides},
  journal = {eLife},
  year = {2024},
  doi = {10.7554/elife.96190}
}
Kostenlos starten →